Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Related Studies

Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This study has been completed.

Study NCT00001287. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Demyelinating Diseases
		Paraproteinemias

2	Additional conditions recognized in this trial
		Polyneuropathies

3	More general conditions related to this trial
		Blood Protein Disorders
		Hematologic Diseases
		Immune System Diseases
		Immunoproliferative Disorders
		Nervous System Diseases
		Neuromuscular Diseases
		Peripheral Nervous System Diseases

4	Interventions listed in this trial
		intravenous immunoglobulin (IVIg)

5	Additional drug interventions recognized in this trial
		Immunoglobulins
		Immunoglobulins, Intravenous
		Rho(D) Immune Globulin

6	More general drug interventions related to this trial
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs

7	Sponsors listed in this trial
		National Institute of Neurological Disorders and Stroke (NINDS)